Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Current Leases (2022 - 2026)

Edgewise Therapeutics has reported Current Leases over the past 5 years, most recently at $1.0 million for Q1 2026.

  • Quarterly results put Current Leases at $1.0 million for Q1 2026, up 1.6% from a year ago — trailing twelve months through Mar 2026 was $1.0 million (up 1.6% YoY), and the annual figure for FY2025 was $1.0 million, up 1.81%.
  • Current Leases reached $1.0 million in Q1 2026 per EWTX's latest filing, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.0 million in Q1 2026 and bottomed at $104000.0 in Q2 2022.
  • Median Current Leases over the past 5 years was $986000.0 (2024), compared with a mean of $844062.5.
  • The largest annual shift saw Current Leases soared 738.46% in 2023 before it increased 1.6% in 2026.
  • Over 5 years, Current Leases stood at $608000.0 in 2022, then soared by 61.18% to $980000.0 in 2023, then rose by 1.63% to $996000.0 in 2024, then increased by 1.81% to $1.0 million in 2025, then increased by 0.3% to $1.0 million in 2026.
  • Business Quant data shows Current Leases for EWTX at $1.0 million in Q1 2026, $1.0 million in Q4 2025, and $1.0 million in Q3 2025.